MedTrace Logo

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

NCT02975700 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-01-13

Study results available
· View outcomes & findings →

Summary

The purpose of this Phase I/II study is to evaluate safety, pharmacokinetics, and preliminary efficacy of the investigational drug PLX3397 in subjects with unresectable or metastatic KIT-mutated melanoma.

Conditions

Interventions

DRUG

PLX3397

1000 mg/day (400 mg in the morning and 600 mg in the evening)

Sponsors & Collaborators

  • Daiichi Sankyo

    collaborator INDUSTRY

  • Daiichi Sankyo Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-08-31
Completion
2024-10-11

Countries

  • China
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02975700 on ClinicalTrials.gov